Human Gene Set: GSE339_EX_VIVO_VS_IN_CULTURE_CD4POS_DC_DN


Standard name GSE339_EX_VIVO_VS_IN_CULTURE_CD4POS_DC_DN
Systematic name M5130
Brief description Genes down-regulated in comparison of ex vivo CD4 [GeneID=920] dendritic cells (DC) versus cultured CD4 [GeneID=920] DCs.
Full description or abstract The functional relationships and properties of different sub-types of dendritic cells (DC) remain largely undefined. We used a global gene profiling approach to determine gene expression patterns among murine splenic CD11c high DC subsets in an effort to better characterise these cells.
Collection C7: Immunologic Signature
      IMMUNESIGDB: ImmuneSigDB
Source publication Pubmed 12816982   Authors: Edwards AD,Chaussabel D,Tomlinson S,Schulz O,Sher A,Reis e Sousa C
Exact source GSE339_1511_200_DN
Related gene sets (show 17 additional gene sets from the source publication)

(show 181 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Mus musculus
Contributed by Jernej Godec (Dana-Farber Cancer Institute)
Source platform or
identifier namespace
HUMAN_GENE_SYMBOL
Dataset references (show 1 datasets)
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 200 genes
Gene families ? Categorize these 200 genes by gene family
Show members (show 200 source identifiers mapped to 200 genes)
Version history 7.3: Moved to ImmuneSigDB sub-collection.

A big thank you to everyone who responded to our request for emails of support for our grant application resubmission.
Reading them made us feel so appreciated and valued by all of you.

We hope we can continue to bring you GSEA/MSigDB in the years to come.
-The GSEA/MSigDB Team


See MSigDB license terms here. Please note that certain gene sets have special access terms.